Marshall Fordyce sold $650k of VERA
PRESIDENT AND CEO at Vera Therapeutics, Inc.. 18,500 shares at an average of $35.12, traded Sep 2, 2026, filed Sep 4, 2026.
Score components
- +25RoleCEO
- +20Trade size$650k at market
- 0Share of holdings soldSold 7.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001859453-26-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | MOption exercise Class A Common Stock10b5-1 | +18,500 | $2.90 | $54k | 253,744 | 38 d ago |
| Sep 2, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -18,500 | $35.12 | $650k | 235,244 | 38 d ago |
| Sep 2, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,500 | $0.00 | $0 | 507,301 | 38 d ago |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 39Weak | Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 61Notable | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $711k 16,925 shares | -6% | |
| 49Moderate | Vera Therapeutics, Inc. | Sean Grant CHIEF FINANCIAL OFFICER | $208k 4,949 shares | -4% | |
| 45Moderate | Vera Therapeutics, Inc. | David Lee Johnson Chief Operating Officer | $108k 2,579 shares | -5% | |
| 38Weak | Vera Therapeutics, Inc. | Laurence Matthew Skelton Chief Commercial Officer | $66k 1,582 shares | -2% | |
| 39Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $92k 2,187 shares | -5% | |
| 41Moderate | Vera Therapeutics, Inc. | Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR | $131k 3,117 shares | -5% | |
| 8Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $501k 10,000 shares | -31% | |
| 36Weak | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $250k 5,882 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.